At DemeRx, we are dedicated to pioneering transformative neuroplastogen medications that empower individuals in recovery from addiction disorders. Our vision is to revolutionize the way addiction is treated and to provide new hope for those affected by alcohol and drugs abuse. This effort will contribute to the overall improvement of public health.
About Us
Our Mission
Our Foundation
Our foundation is built on the groundbreaking work of Dr. Deborah Mash, our founder and Chief Executive Officer. Dr. Mash’s innovative research on the neuroplastogen noribogaine, the active metabolite of ibogaine, has positioned DemeRx at the forefront of what is possible in addiction therapeutics.
Chronic misuse of alcohol and drugs disrupts brain wiring, creating a compulsive drive for substances despite harmful consequences. By leveraging the neuroplasticity induced by noribogaine, we aim to restore and reset the brain’s addiction circuitry, facilitating a faster and more effective treatment of substance use disorders.
Deborah Mash, PhD, CEO and Founder
Our leadership bring together a wealth of experience in drug development, addiction treatment, pharmaceuticals, and neuroscience. With a strong track record of conducting cutting edge research and clinical development, navigating regulatory approvals, and launching innovative products, we are committed to delivering for patients at DemeRx.
